Evercore ISI initiated coverage of Jasper Therapeutics with an Outperform rating and $65 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Jasper Therapeutics initiated with an Outperform at RBC Capital
- Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
- Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria